NeuroPhage Pharmaceuticals Garners $17,000,000 Series D Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ce5ffeb2-f95f-437a-9bfc-93acc3207129 - Date
3/25/2014 - Company Name
NeuroPhage Pharmaceuticals - Mailing Address
222 3rd St. Cambridge, MA 02142 USA - Company Description
NeuroPhage is developing a breakthrough protein dissaggregation platform for treatment of neurodegenerative diseases. Our lead Alzheimer’s disease (AD) drug candidate, NPT001, safely and effectively dissaggregates existing Aß plaque in preclinical animal models, which is unique among disease-modifying approaches for AD. - Website
http://www.neurophage.com - Transaction Type
Venture Equity - Transaction Amount
$17,000,000 - Transaction Round
Series D - Proceeds Purposes
This substantial financing will enable NeuroPhage to progress a robust IND-enabling package for NPT088 and prepare for the clinical evaluation of a completely new approach to treat devastating neurological diseases. - M&A Terms
- Venture Investor
